ArticleJCO global oncology2021
Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420).
Article in JCO global oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Patient care and access to clinical trials in gynaecological oncology: global implications of the early phase of the COVID-19 pandemic.Archives of gynecology and obstetrics · 2024Article
- Researcher Experience and Comfort With Telemedicine and Remote Patient Monitoring in Cancer Treatment Trials.The oncologist · 2024Article
- Narrative review of telemedicine applications in decentralized research.Journal of clinical and translational science · 2024Review
- Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic.JCO oncology practice · 2023Article
- The Impact of a National Cyberattack Affecting Clinical Trials: The Cancer Trials Ireland Experience.JCO clinical cancer informatics · 2023Article
- Sleep Quality, Insomnia, and Perceived Stress among Colombian Healthcare Workers during the COVID-19 Pandemic.Sleep science (Sao Paulo, Brazil) · 2023Article
- Despite negative perceptions of clinical trial conduct during the coronavirus disease 2019 (COVID-19) pandemic, are decentralized clinical trial methods here to stay?Annals of translational medicine · 2023Article
- A single experience in the conduction of clinical trial during COronaVIrusDisease-2019 pandemic.Exploration of targeted anti-tumor therapy · 2023Article
- Impact of the COVID-19 pandemic on clinical trials: a cross-sectional questionnaire study in China.Annals of translational medicine · 2022Article
- Impact of the COVID-19 Pandemic on Breast Cancer Management in Portugal: A Cross-Sectional Survey-Based Study of Medical Oncologists.Oncology and therapy · 2022Article
- Article
- Gynecologic radiation therapy in low and middle income countries during the COVID-19 pandemic.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022Review
- Characterising COVID-19 empirical research production in Latin America and the Caribbean: A scoping review.PloS one · 2022Article
- Global cancer research in the era of COVID-19: a bibliometric analysis.Ecancermedicalscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCOVID-19 has affected cancer care worldwide. Clinical trials are an important alternative for the treatment of oncologic patients, especially in Latin America, where trials can be the only opportunity for some of them to access novel and, sometimes, standard treatments.
methodsThis was a cross-sectional study, in which a 22-question survey regarding the impact of the COVID-19 pandemic on oncology clinical trials was sent to 350 representatives of research programs in selected Latin American institutions, members of the Latin American Cooperative Oncology Group.
resultsThere were 90 research centers participating in the survey, with 70 of them from Brazil. The majority were partly private or fully private (n = 77; 85.6%) and had confirmed COVID-19 cases at the institution (n = 57; 63.3%). Accruals were suspended at least for some studies in 80% (n = 72) of the responses, mostly because of sponsors' decision. Clinical trials' routine was affected by medical visits cancelation, reduction of patients' attendance, reduction of other specialties' availability, and/or alterations on follow-up processes. Formal COVID-19 mitigation policies were adopted in 96.7% of the centers, including remote monitoring and remote site initiation visits, telemedicine visits, reduction of research team workdays or home office, special consent procedures, shipment of oral drugs directly to patients' home, and increase in outpatient diagnostic studies. Importantly, some of these changes were suggested to be part of future oncology clinical trials' routine, particularly the ones regarding remote methods, such as telemedicine.
conclusionTo our knowledge, this was the first survey to evaluate the impact of COVID-19 on Latin American oncology clinical trials. The results are consistent with surveys from other world regions. These findings may endorse improvements in clinical trials' processes and management in the postpandemic period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.